RecruitingEarly Phase 1NCT07680582

An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

An Exploratory Study of Personalized Cancer Vaccine (ABO2109) in Adjuvant Therapy of Solid Tumors

Sponsor

Ruijin Hospital

Enrollment

60 participants

Start Date

Jun 9, 2026

Study Type

INTERVENTIONAL

Conditions

Solid Tumor

Summary

The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ABO2109 Injection and a drug called Toripalimab for people with solid tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.